The U.S. Food and Drug Administration (FDA) has granted breakthrough designation to soficabtagene geleucel (sofi-cel), a cell therapy designed to treat relapsed or refractory T-cell…
News
After a year of treatment with the experimental medication atebimetinib as an add-on to chemotherapy, about two-thirds of pancreatic cancer patients in an ongoing…
Curasight‘s experimental cancer therapy, uTREAT, has successfully reached its target in the brain of the first patient dosed in a Phase 1 clinical trial.
The U.S. Food and Drug Administration (FDA) has granted its breakthrough therapy designation to sofetabart mipitecan as a potential treatment for people with platinum-resistant epithelial…
Treatment with Tecvayli (teclistamab) was better than standard therapies at delaying disease progression and prolonging survival among previously-treated myeloma patients in a Phase…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NP-G2-044, an experimental treatment for pancreatic cancer that’s currently in clinical…
Treatment with DeltEx DRI, a cell therapy developed by In8bio, is prolonging survival outcomes among people with newly diagnosed glioblastoma in a clinical…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to ETX-19477, an oral treatment for ovarian cancer currently in early clinical testing.
Johnson & Johnson is now seeking regulatory approval in the European Union for Tecvayli (teclistamab) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) for…
All four adults with hard-to-treat acute myeloid leukemia (AML) who received treatment with a combination of Venclexta (venetoclax) and AB Science‘s experimental therapy AB8939…
